Van Poznak, C.H., Temin, S., Yee, G.C., Janjan, N.A., Barlow, W.E., Bierman, J.S., . . . Von Roenn, J.H., (2011). American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Retrieved from http://www.asco.org/sites/www.asco.org/files/full_bma_gline_u5209.pdf
To update the American Society of Clinical Oncology Guidelines regarding the role of bone-modifying agents (BMAs) in the treatment of metastatic breast cancer
Databases searched were MEDLINE and the Cochrane Library to July 2009. Investigators performed a supplemental search of items published through November 2010. Studies selected were those in which patients were randomly assigned to receive a BMA or placebo or alternative intervention. Subjects had metastatic breast cancer. Recommendations were developed by consensus following review of the evidence.
The clinical guideline update made the recommendations that follow.
Bone-modifying agents are recommended for patients with metastatic breast cancer who have evidence of bone destruction as an adjunct to standard pain management.